In a significant advancement for xenotransplantation, researchers in China have successfully performed the world’s first simultaneous transplant of two gene-edited pig kidneys and a liver into a human patient. The procedure, conducted on a 53-year-old brain-dead male, represents a major technical milestone in the effort to address the global shortage of human organs for transplant. The transplanted organs maintained normal function for five days, providing critical data on the viability of multi-organ animal-to-human procedures.
The research team, led by Xuyong Sun, director of the Institute of Transplantation at Guangxi Medical University’s Second Affiliated Hospital, utilized CRISPR gene-editing technology to modify the donor organs. By removing three pig genes and adding three human genes, the team aimed to mitigate the immediate immune rejection typically associated with cross-species transplantation. The findings, which were published in the international medical journal Med, offer a new proof-of-concept for complex xenotransplantation.
Technical Execution and Organ Function
The surgical team reported that the transplanted pig liver began producing bile approximately 19 hours after the procedure, a key indicator of normal physiological function. Simultaneously, the two pig kidneys successfully addressed the patient’s elevated creatinine and urea levels, which had been caused by chronic kidney disease. This dual-organ success demonstrates that multiple genetically modified organs can function in tandem within a human host, at least in the short term.
Despite the initial success, the team noted that signs of rejection began to manifest after 36 hours. This included partial liver necrosis and the formation of blood clots. While the organs did not sustain long-term viability, the researchers emphasized that the five-day window provided invaluable insights into the immunological challenges of multi-organ xenotransplantation. The team stated, “While not a complete success, this surgery provided insights into reducing immune rejection. We aim to enable patients struggling to find organs to undergo xenotransplantation through further research.”
Addressing the Global Organ Shortage
The medical necessity for such procedures is underscored by the severe global deficit of human organ donors. Current data indicates that fewer than 10 percent of patients on transplant waiting lists successfully receive a surgery. In the United States alone, the waiting list exceeds 103,000 individuals, with 89,000 requiring kidney transplants and nearly 10,000 awaiting liver transplants. The inability to secure timely donors results in an average of 17 deaths per day in the U.S. alone.
By exploring the potential of gene-edited animal organs, the scientific community hopes to eventually bridge this gap. The success of this simultaneous transplant suggests that the complexity of replacing multiple organs may be surmountable with continued refinement of CRISPR techniques. The research team’s ability to maintain function for five days serves as a benchmark for future clinical trials, though significant hurdles regarding long-term immune suppression and organ rejection remain to be solved.
Ethical and Clinical Considerations
The use of a brain-dead patient for this procedure was conducted with full family consent, adhering to established ethical protocols for experimental medical research. This approach allows researchers to observe the immediate physiological response of human systems to animal organs without the risks associated with living human subjects. The data gathered from this five-day observation period is expected to inform future iterations of gene-editing protocols, specifically targeting the mechanisms that led to the rejection observed after the 36-hour mark.
As the field of xenotransplantation evolves, the focus remains on extending the survival time of these grafts. The Chinese team’s work highlights the necessity of balancing genetic modification with the body’s complex immune response. Future research will likely focus on refining the gene-editing cocktail to further delay or prevent the necrosis and clotting issues encountered in this study. The medical community continues to monitor these developments as a potential pathway to transforming the standard of care for end-stage organ failure.
